Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Masimo Corp (NQ: MASI )

162.41 +1.06 (+0.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Masimo Corp

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Masimo: Q1 Earnings Insights
Via Benzinga
Masimo Reports First Quarter 2023 Financial Results
From Masimo
Via Business Wire
A Preview Of Masimo's Earnings
Via Benzinga
Cambridge University Hospitals Expands Virtual Care Program with Masimo W1™
From Masimo
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Masimo Corp. (NASDAQ: MASI) Records 52-Week High Thursday Morning
Via Investor Brand Network
Expert Ratings for Masimo
Via Benzinga
Politan Nominates Two Candidates for Masimo Board
From Politan Capital Management
Via Business Wire
Masimo Stork™ Delivers State-of-the-Art Baby Monitoring to the Home
From Masimo
Via Business Wire
Masimo to Report First Quarter 2023 Financial Results After Market Close on Tuesday, May 9
From Masimo
Via Business Wire
Masimo Announces FDA Clearance of the Rad-G® with Temperature
From Masimo
Via Business Wire
Shockwave Medical Stock With Rising Relative Strength
On Tuesday, Shockwave Medical stock received an upgrade to its Relative Strength (RS) Rating, from 67 to 75. 
Via Investor's Business Daily
Masimo Opioid Halo™ Granted De Novo for the First and Only FDA-Authorized Opioid Overdose Prevention and Alert System
From Masimo
Via Business Wire
Masimo Unveils the Future of Health Tracking and Smart Wearables with the Pre-Sale Launch of the Freedom™ Smartwatch
From Masimo
Via Business Wire
Masimo Announces Changes to Governance Structure and Practices
From Masimo Corporation
Via Business Wire
European Society of Anaesthesiology and Intensive Care (ESAIC) Recommends Noninvasive, Continuous Hemoglobin Monitoring
From Masimo
Via Business Wire
New Study Finds That Masimo PVi® Reliably Predicted Fluid Responsiveness in Young Children Undergoing Neurosurgery
From Masimo
Via Business Wire
Masimo and Temple Health Form Innovation Collaboration with Focus on Hospital Automation and Telehealth Initiatives
From Masimo
Via Business Wire
New Study Evaluates the Use of Masimo PVi® As an Indicator of Fluid Responsiveness to Guide Goal-Directed Fluid Therapy in Adult Neurosurgical Patients
From Masimo
Via Business Wire
$300B California Teachers Pension Fund Joins Politan Capital In Legal Action Against Masimo CEO's Employment Agreement
Via Benzinga
CalSTRS Joins Politan Capital Management in Legal Action Against Masimo CEO’s Employment Agreement
From Politan Capital Management
Via Business Wire
Masimo to Present in 44th Annual Raymond James Institutional Investors Conference
From Masimo
Via Business Wire
Masimo Reports Fourth Quarter and Full-Year 2022 Financial Results
From Masimo
Via Business Wire
Analyst Says This MedTech Giant Stock Offers 'Too Much Optionality,' Upgrades Rating
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023
Via Benzinga
New Study Evaluates the Utility of Masimo ORi™ in Reducing Hyperoxemia During Laparoscopic Gastrectomy
From Masimo
Via Business Wire
Masimo Centroid® Receives Innovative Technology Designation from Vizient
From Masimo
Via Business Wire
Masimo to Report Fourth Quarter and FY 2022 Financial Results After Market Close on Tuesday, February 28
From Masimo
Via Business Wire
Thoughts For Thursday: Risk-off, Risk-on
The one foot forward, one foot backward action continues on Wall Street, though yesterday it was more like three or four steps backward. It seems Q1 earnings jitters are responsible. 
Via Talk Markets
NeurAxis: Should You Buy This IPO?
As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype. 
Via Talk Markets
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.